Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Dec 3;4(3):370-371.
doi: 10.1016/j.ekir.2018.10.022. eCollection 2019 Mar.

Long-term Use of Eculizumab in Kidney Transplant Recipients

Sabrina Milan Manani  1   2 , Grazia Maria Virzì  1   2 , Claudio Ronco  1   2
Affiliations
Editorial

Long-term Use of Eculizumab in Kidney Transplant Recipients

Sabrina Milan Manani et al. Kidney Int Rep. .
No abstract available

PubMed Disclaimer

References

    1. Legendre C.M., Licht C., Muus P. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–2181. - PubMed
    1. Nester C.M., Thomas C.P. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology Am Soc Hematol Educ Program. 2012;2012:617–625. - PubMed
    1. Zuber J., Le Quintrec M., Krid S. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12:3337–3354. - PubMed
    1. Le Quintrec M., Zuber J., Moulin B. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13:663–675. - PubMed
    1. Milan Manani S., Virzi G.M., Giuliani A. Hemolytic uremic syndrome and kidney transplantation: a case series and review of the literature. Nephron. 2017;136:245–253. - PubMed

Publication types

LinkOut - more resources